The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 9, 2006, Pages 3521-3527

  Jang, Yangsoo ^a,b   Oh, Yoen Kim ^b   Soo, Jeong Koh ^a,b   Jey, Sook Chae ^b   Young, Guk Ko ^a,b   Ji, Young Kim ^b,c   Cho, Hongkeun ^b   Jeong, Tae Sook ^d   Woo, Song Lee ^d   Ordovas, Jose M ^e   Jong, Ho Lee ^a,b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c DNA Link Inc   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLVALINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; LIPID PEROXIDE; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 ENZYME; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHENYLALANINE DERIVATIVE; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; VALINE; VALYLPHENYLALANINE;

ADULT; ALCOHOL CONSUMPTION; ALLELE; AMINO ACID SEQUENCE; ANTHROPOMETRY; ARTICLE; BODY MASS; CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATALYSIS; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KOREA; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 33748752140     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0116     Document Type: Article

References (33)

1. 2) deficiency patients. J Hum Genet 49:302-307
2. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota K 2000 Correlation between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150:209-216
3. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K 1997 A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke 28:2417-2420
4. 994→T mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47:177-181
5. Sudhir K 2005 Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 90:3100-3105
6. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA 2000 The Ile198The and Ala379Val variants of plasmatic PAF-acetylhydolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66:1522-1530
7. Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, Rupprecht HJ, Cambien F, Blankenberg S, Tiret L 2004 Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 13:1341-1351
8. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ 2003 Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168:283-288
9. 2 inhibitors. Bioorg Med Chem Lett 15:1525-1527
10. Buckingum KW 1985 Effect of dietary polyunsaturated/saturated fatty acid ratio and dietary vitamin E on lipid peroxidation in the rat. J Nutr 115:1425-1435
11. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M 1988 Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82:1983-1991
12. Naoki K, Asano K, Satoh N, Fukunaga K, Oguma T, Shiomi T, Suzuki Y, Nakajima T, Niimi K, Shiraishi Y, Ishizaka A, Yamaguchi K 2004 PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency. Biochem Biophys Res Commun 317:205-210
13. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M 2003 Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42:93-114
14. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM 1996 Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97:2784-2791
15. Murakami M, Kudo I 2002 Phospholipase A2. J Biochem (Tokyo) 131:285-292
16. Kim PS, Arvan P 1998 Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 19:173-202
17. Zhang K, Kaufman RJ 2004 Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 279:25935-25938
18. Yamamoto I, Fujitsu J, Nohnen S, Igarashi T, Motomura T, Inaba M, Tsubakimori S, Azuma J 2003 Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 59:219-224
19. 2, platelet-activating factor cetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150:413-419
20. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM 2001 A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38:1302-1306
21. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD 2000 Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148-1155
22. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E 2003 Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44:1381-1386
23. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB 2005 Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26:137-144
24. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR 2004 Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837-842
25. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC 2005 Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111:570-575
26. Macphee CH 2001 Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 1:121-125
27. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD 1994 Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1213:34-38
28. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC 1997 Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res 38:2281-2288
29. Tselepis AD, John Chapman M 2002 Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3:57-68
30. Rosenson RS, Otvos JD, Freedman DS 2002 Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90:89-94
31. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR, DAIS Group 2003 Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733-1737
32. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W 2005 Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111:980-987
33. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W 2004 Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89:1153-1159